56181-39-6

Basic information

• Product Name: 4-Chloro-5-Bromopyrimidine
• Synonyms: 4-Chloro-5-Bromopyrimidine;4-Chloro-5-bromopyrimidin...;Pyrimidine, 5-bromo-4-chloro-
• CAS NO: 56181-39-6
• Molecular Formula: C₄H₂BrClN₂
• Molecular Weight: 193.44
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 56181-39-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 250.662 °C at 760 mmHg
• Flash Point: 105.397 °C
• Appearance: /
• Density: 1.86 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.41±0.16(Predicted)
• CAS DataBase Reference: 4-Chloro-5-Bromopyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-5-Bromopyrimidine(56181-39-6)
• EPA Substance Registry System: 4-Chloro-5-Bromopyrimidine(56181-39-6)

Safety Data

• Hazardous Substances Data: 56181-39-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C4H2BrClN2/c5-3-1-7-2-8-4(3)6/h1-2H

Upstream product

• 19808-30-1 5-bromo-4(3H)-pyrimidinone 
• 19808-30-1 5-bromo-4-hydroxypyrimidine 
• 10025-87-3 trichlorophosphate 

Downstream Products

• 1439-10-7 4-amino-5-bromopyrimidine 
• 4319-85-1 5-bromo-4-methoxy-pyrimidine 
• 1232361-96-4 4-(benzyloxy)-5-bromopyrimidine 
• 1425045-78-8 C₂₁H₁₆BrClN₄O 

Relevant articles and documents

PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS

Compounds of the general formula(I): (I) processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3,4-B] PYRIDINE AND PYRAZOLO [3,4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3,4-b] pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo [3,4-b] pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson?s disease, Alzheimer?s disease, Down?s Syndrome, Huntington?s disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated there with using compounds and pharmaceutical compositions including the compounds.

Process chemistry related to the experimental rice herbicide 2,2-dimethyl-1-(4-methylthio-5-pyrimidinyl)indane

Two concise syntheses of the experimental rice herbicide 2,2-dimethyl-1-(4-methylthio-5-pyrimidinyl)indane are reported. The initial synthesis relies on a low-temperature addition of 5-lithio-4-methylthiopyrimidine to 2,2-dimethyl-1-indanone to construct the pyrimidinylindane system. Process improvements to this route are described and resulted in the preparation of 90 kg of the title compound on pilot plant scale. Economics dictated the need to identify a new synthetic route which utilized inexpensive raw materials. Detailed herein is the initial discovery of a new route which features a novel combination of dissolving metal reduction/formylation/cyclization to construct the requisite pyrimidine ring. Process improvements to this chemistry have allowed us to deliver an appropriately substituted pyrimidinylindane in a minimal number of synthetic operations.